BRCA-negative high-grade serous ovarian cancer with recurrent progression: A clinical case

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Case analysis reveals challenges of treating BRCA-negative high-grade serous ovarian cancer, suggesting limited PARP inhibitor efficacy.

The patient exhibited multiple disease progressions despite receiving five lines of chemotherapy, highlighting treatment challenges.
Molecular analysis indicated the absence of BRCA1/2 mutations while showing a homologous recombination deficiency score of 20.1%.
Treatment included various drugs, yet the tumor remained resistant, leading to a transition to palliative care.
This case underscores the urgent need for personalized treatment approaches for patients with unfavorable molecular profiles.

Aidarov et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark